According to the latest report published by Credence Research, Inc. “Human Chorionic Gonadotropin Market (Treatments: Female Infertility, Oligospermia, Cryptorchidism & Others; Technology: Natural Source Extraction & Recombinant DNA Technology): Growth, Future Prospects and Competitive Analysis, 2016-2022,” the human chorionic gonadotropin market was valued at USD346.3 Mn in 2015, and is expected to reach USD533.7Mn by 2022, expanding at a CAGR of 6% from 2016 to 2022.
Browse the full report Human Chorionic Gonadotropin:Market Growth, Future Prospects and Competitive Analysis, 2016-2022 at http://www.credenceresearch.com/report/human-chorionic-gonadotropin-market
Infertility treatment in both males and females is the major treatment area whereHCG is commonly administered. Growing incidence of infertility in women,contributed by increased maternity age, lifestyle effects and others, hormonaldysfunctions in men and growing incidence of oligospermia are the key factors thathave supported the demand for HCG drugs in the market. The demand for HCG issteady in developed markets of Europe and North America. On the other hand,growing awareness in general population and development of healthcareinfrastructure are supporting the growth in demand for HCG drugs in emergingmarkets.
HCG supports the normal development of egg in ovary and stimulates egg release during ovulation. It is also used for infertility treatment in women and to augmentsperm count in men. Young boys with undescended testicles are also administeredHCG treatment. Hugh prevalence of both male and female infertility issues,expanding incidence of low sperm count and sperm density in men are is the keyfactor driving the HCG drugs market. A majority of the products currently availablein the market are natural source, i.e. urine derived HCG. However, in view of batchto batch inconsistency in product purity and requirement of large amount of urinehas resulted in emergence of recombinant production technology.
North America is expected to be the largest and most potential regional market forhuman chorionic gonadotropin. North America constitutes regional markets of U.S.and Canada, the rising incidence of infertility cases, lifestyle effects and others,hormonal dysfunctions in men and women are the major driver for the growth ofthe global human chorionic gonadotropin market. Asia-Pacific is the expected to bethe most potential regional market for human chorionic gonadotropin market by2022. Over the next six years, the growth of the market in the Asia-Pacific region islikely to be centered in Japan, South Korea, China, and India.The key players in human chorionic gonadotropin market are EMD Serono, Inc.,Ferring B.V., Merck & Co., Inc., Bristol Myers Squibb Company and Fresenius KabiUSA, LLC.